DK200201741A - Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum - Google Patents

Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum Download PDF

Info

Publication number
DK200201741A
DK200201741A DK200201741A DKPA200201741A DK200201741A DK 200201741 A DK200201741 A DK 200201741A DK 200201741 A DK200201741 A DK 200201741A DK PA200201741 A DKPA200201741 A DK PA200201741A DK 200201741 A DK200201741 A DK 200201741A
Authority
DK
Denmark
Prior art keywords
plasmodium
protein
merozoite surface
falcinarum
surface protein
Prior art date
Application number
DK200201741A
Other languages
Danish (da)
English (en)
Inventor
Theisen Michael
Jepsen Soeren
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Priority to DK200201741A priority Critical patent/DK200201741A/da
Publication of DK200201741A publication Critical patent/DK200201741A/da
Priority to AT03810941T priority patent/ATE432081T1/de
Priority to BR0315205-7A priority patent/BR0315205A/pt
Priority to CN2003801031543A priority patent/CN1741815B/zh
Priority to ES03810941T priority patent/ES2326415T3/es
Priority to CA2505724A priority patent/CA2505724C/en
Priority to EP03810941A priority patent/EP1567189B1/de
Priority to PCT/DK2003/000759 priority patent/WO2004043488A1/en
Priority to DE60327801T priority patent/DE60327801D1/de
Priority to AU2003275949A priority patent/AU2003275949B2/en
Priority to DK03810941T priority patent/DK1567189T3/da
Priority to JP2005506641A priority patent/JP4573773B2/ja
Priority to US11/128,660 priority patent/US7749507B2/en
Priority to ZA200504415A priority patent/ZA200504415B/en
Priority to HK06102595.9A priority patent/HK1080754A1/xx
Priority to US12/793,575 priority patent/US20110020387A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445Plasmodium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/015Hemosporidia antigens, e.g. Plasmodium antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK200201741A 2002-11-12 2002-11-12 Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum DK200201741A (da)

Priority Applications (16)

Application Number Priority Date Filing Date Title
DK200201741A DK200201741A (da) 2002-11-12 2002-11-12 Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
JP2005506641A JP4573773B2 (ja) 2002-11-12 2003-11-06 マラリア・ワクチン
EP03810941A EP1567189B1 (de) 2002-11-12 2003-11-06 Malaria-vakzine
DE60327801T DE60327801D1 (de) 2002-11-12 2003-11-06 Malaria-vakzine
CN2003801031543A CN1741815B (zh) 2002-11-12 2003-11-06 疟疾疫苗
ES03810941T ES2326415T3 (es) 2002-11-12 2003-11-06 Vacuna contra la malaria.
CA2505724A CA2505724C (en) 2002-11-12 2003-11-06 Malaria vaccine
AT03810941T ATE432081T1 (de) 2002-11-12 2003-11-06 Malaria-vakzine
PCT/DK2003/000759 WO2004043488A1 (en) 2002-11-12 2003-11-06 Malaria vaccine
BR0315205-7A BR0315205A (pt) 2002-11-12 2003-11-06 Vacina baseada em antìgeno contra malária, proteìna de fusão, processo para preparação da mesma, ácido nucleico, e, uso do mesmo
AU2003275949A AU2003275949B2 (en) 2002-11-12 2003-11-06 Malaria vaccine
DK03810941T DK1567189T3 (da) 2002-11-12 2003-11-06 Malariavaccine
US11/128,660 US7749507B2 (en) 2002-11-12 2005-05-12 Malaria vaccine
ZA200504415A ZA200504415B (en) 2002-11-12 2006-01-17 Malaria vaccine
HK06102595.9A HK1080754A1 (en) 2002-11-12 2006-02-27 Malaria vaccine
US12/793,575 US20110020387A1 (en) 2002-11-12 2010-06-03 Malaria vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK200201741A DK200201741A (da) 2002-11-12 2002-11-12 Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
DKPA200301307 2003-09-11

Publications (1)

Publication Number Publication Date
DK200201741A true DK200201741A (da) 2003-09-16

Family

ID=32313776

Family Applications (2)

Application Number Title Priority Date Filing Date
DK200201741A DK200201741A (da) 2002-11-12 2002-11-12 Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
DK03810941T DK1567189T3 (da) 2002-11-12 2003-11-06 Malariavaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK03810941T DK1567189T3 (da) 2002-11-12 2003-11-06 Malariavaccine

Country Status (14)

Country Link
US (2) US7749507B2 (de)
EP (1) EP1567189B1 (de)
JP (1) JP4573773B2 (de)
CN (1) CN1741815B (de)
AT (1) ATE432081T1 (de)
AU (1) AU2003275949B2 (de)
BR (1) BR0315205A (de)
CA (1) CA2505724C (de)
DE (1) DE60327801D1 (de)
DK (2) DK200201741A (de)
ES (1) ES2326415T3 (de)
HK (1) HK1080754A1 (de)
WO (1) WO2004043488A1 (de)
ZA (1) ZA200504415B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
US20030161840A1 (en) * 1992-10-19 2003-08-28 Institut Pasteur Plasmodium falciparum antigens inducing protective antibodies
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
US20050112133A1 (en) * 2003-10-24 2005-05-26 Pierre Druilhe GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
US7488489B2 (en) * 2004-08-03 2009-02-10 Institut Pasteur Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies
EP2818175B1 (de) * 2009-05-05 2018-11-21 Cadila Healthcare Limited Kombinierter Impfstoff gegen Masern und Malaria
CN102471361B (zh) 2009-07-15 2016-06-01 不列颠哥伦比亚大学 作为神经氨酸酶抑制剂的2,3-氟化糖苷及其作为抗病毒药物的用途
DK2385107T3 (en) * 2010-05-03 2016-12-12 Pasteur Institut Lentiviral vector-based immunological compounds against malaria
DK2763694T3 (en) 2011-10-04 2018-04-16 Statens Seruminstitut Preparation of a cysteine-rich protein
WO2013082394A1 (en) * 2011-11-30 2013-06-06 The Regents Of The University Of California Immunogenic plasmodium falciparum antigen compositions and uses thereof
CN102533677B (zh) * 2012-01-10 2013-07-24 特菲(天津)生物医药科技有限公司 一种疟疾疫苗及其制备方法
KR102128413B1 (ko) 2012-01-19 2020-07-01 더 유니버시티 오브 브리티쉬 콜롬비아 3' 적도방향 불소 치환된 뉴라미니다제 저해제 화합물 및 항바이러스제로 사용하기 위한 이의 조성물 및 방법
CN105628928A (zh) * 2014-11-11 2016-06-01 深圳国际旅行卫生保健中心 可用于辅助诊断疟疾的试剂盒
CN105652009B (zh) * 2014-11-11 2018-04-24 中国科学院苏州纳米技术与纳米仿生研究所 可用于辅助诊断疟疾的试剂盒
MX2018014253A (es) 2016-05-19 2019-11-11 Univ Pennsylvania Inmunógenos de malaria sintéticos, combinaciones de estos y su uso para prevenir y tratar infecciones de malaria.
WO2018017020A1 (en) * 2016-07-21 2018-01-25 Vac4All Pte. Ltd. Biofusion proteins as anti-malaria vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231168A (en) * 1988-09-16 1993-07-27 Statens Seruminstitut Malaria antigen
DK519188D0 (da) * 1988-09-16 1988-09-16 Statens Seruminstitut Kemisk forbindelse
AU645482B2 (en) * 1988-09-16 1994-01-20 Statens Serum Institut A malaria antigen
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
JP2002537354A (ja) * 1999-02-25 2002-11-05 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ペプチド、及びH.influenzaeのプロテインD由来の担体を含む免疫原
WO2002092628A2 (fr) * 2001-05-16 2002-11-21 Institut Pasteur Antigenes de plasmodium falciparum et leurs applications vaccinales et diagnostiques
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum

Also Published As

Publication number Publication date
DE60327801D1 (de) 2009-07-09
ATE432081T1 (de) 2009-06-15
JP4573773B2 (ja) 2010-11-04
EP1567189B1 (de) 2009-05-27
ZA200504415B (en) 2006-03-29
DK1567189T3 (da) 2009-09-14
ES2326415T3 (es) 2009-10-09
AU2003275949B2 (en) 2008-06-05
US20060024324A1 (en) 2006-02-02
BR0315205A (pt) 2005-08-16
AU2003275949A1 (en) 2004-06-03
CA2505724C (en) 2015-06-30
US7749507B2 (en) 2010-07-06
CN1741815B (zh) 2010-05-26
HK1080754A1 (en) 2006-05-04
CN1741815A (zh) 2006-03-01
JP2006512926A (ja) 2006-04-20
US20110020387A1 (en) 2011-01-27
CA2505724A1 (en) 2004-05-27
WO2004043488A1 (en) 2004-05-27
EP1567189A1 (de) 2005-08-31

Similar Documents

Publication Publication Date Title
DK200201741A (da) Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
Acquah et al. Transmission-blocking vaccines: old friends and new prospects
Eichinger et al. Circumsporozoite protein of Plasmodium berghei: gene cloning and identification of the immunodominant epitopes
Moelans et al. A novel protein antigen of the malaria parasite Plasmodium falciparum, located on the surface of gametes and sporozoites
ES2218520T3 (es) Antigenos de plasmodium falciparum inductores de anticuerpos protectores.
Sinnis et al. Cell invasion by the vertebrate stages of Plasmodium
Renia et al. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge
Fidock et al. Cloning and characterization of a novel Plasmodium falciparum sporozoite surface antigen, STARP
Lobo et al. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies
Williamson Pfs230: from malaria transmission-blocking vaccine candidate toward function.
FR2744724B1 (fr) Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
Webster et al. Progress with new malaria vaccines
JP2006512926A5 (de)
RU2007109608A (ru) Вакцины, содержащие антиген plasmodium
Yoshida et al. Direct immunization of malaria DNA vaccine into the liver by gene gun protects against lethal challenge of Plasmodium berghei sporozoite
Robson et al. Cloning and expression of the thrombospondin related adhesive protein gene of Plasmodium berghei
Hviid Clinical disease, immunity and protection against Plasmodium falciparum malaria in populations living in endemic areas
Patarroyo et al. Functionally relevant proteins in Plasmodium falciparum host cell invasion
WO1997030159A3 (fr) Proteine recombinante contenant un fragment c-terminal de msp-1 tde plasmodium
US5217898A (en) Expression of the P. falciparum transmission-blocking antigen in yeast
IL90134A0 (en) Gene for encoding a human malaria vaccine antigen,malarial vaccines and pharmaceutical compositions
BR9604989A (pt) Polipeptídeos modificados para imunogenicidade aperfeiçoada e processo de sua produção
Zhang et al. Construction and evaluation of a multistage combination vaccine against malaria
DE60235044D1 (de) REKOMBINANTES, 250 kDa GROSSES ANTIGEN AUS SPOROZOITEN/MEROZOITEN VON EIMERIA MAXIMA CODIERENDE NUKLEINSÄUREN UND IHRE VERWENDUNGEN
EP0254862A1 (de) Impfstoffe gegen protozoischen Parasiten

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment